Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Liver Diseases

  Free Subscription


22.12.2025

2 Am J Gastroenterol
3 Biochem Biophys Res Commun
1 BMC Cancer
6 BMC Gastroenterol
1 Dig Dis Sci
2 Endoscopy
1 Eur J Pediatr
2 Eur Radiol
1 Gastrointest Endosc
12 Hepatology
2 J Clin Oncol
7 J Hepatol
1 N Engl J Med
2 PLoS One
2 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Gastroenterol

  1. SHROFF H, Fix OK
    Practical Applications of Artificial Intelligence to Improve Efficiency and Reduce Burnout in Gastroenterology and Hepatology Practices.
    Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003887.
    PubMed        

  2. CHOI J, Nguyen VH, Przybyszewski E, Song J, et al
    Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 Diabetes.
    Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003889.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  3. RASINENI K, Rajamanickam R, Perumal SK, Osna NA, et al
    Betaine supplementation prevents ethanol-induced disruption of intestinal tight junction integrity and liver inflammation in rats.
    Biochem Biophys Res Commun. 2026;794:152997.
    PubMed         Abstract available

  4. ZHU Y, Hu M, Xu R, Zhai J, et al
    TARDBP upregulates GJB2 to promote tumor progression in hepatocellular carcinoma.
    Biochem Biophys Res Commun. 2025;796:153123.
    PubMed         Abstract available

  5. YANG S, Ko M, Zhang W, Jeong SM, et al
    Splicing factor SF3B4 promotes mitochondrial glutamine metabolism in hepatocellular carcinoma by regulating GLS1 isoform switching.
    Biochem Biophys Res Commun. 2025;796:153134.
    PubMed         Abstract available


    BMC Cancer

  6. WANG Z, Zhu J, Zhang W, Yang Z, et al
    Association of the YTHDF2 rs3738067 A>G variant with hepatoblastoma risk: a multicenter case-control study in Chinese children.
    BMC Cancer. 2025 Dec 17. doi: 10.1186/s12885-025-15478.
    PubMed        


    BMC Gastroenterol

  7. LONGSOMBOON R, Kachornvitaya P, Prasoppokakorn T, Treeprasertsuk S, et al
    Impact of metabolic and bariatric surgery on MASLD: histological resolution and metabolic outcomes in a retrospective cohort.
    BMC Gastroenterol. 2025;25:864.
    PubMed         Abstract available

  8. YI Y, Chen Y, Luo Y
    Aspirin reduces short-term mortality risk in critically ill patients with liver cirrhosis: a propensity-score matched retrospective analysis using the MIMIC-IV database.
    BMC Gastroenterol. 2025 Dec 18. doi: 10.1186/s12876-025-04499.
    PubMed        

  9. ZHANG S, Akahoshi T, Yoshizumi T, Eto M, et al
    "Noninvasive predictive marker for esophageal variceal bleeding".
    BMC Gastroenterol. 2025 Dec 18. doi: 10.1186/s12876-025-04567.
    PubMed        

  10. HIOKI T, Imoto K, Goya T, Azuma Y, et al
    Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity induced by immune checkpoint inhibitors.
    BMC Gastroenterol. 2025 Dec 17. doi: 10.1186/s12876-025-04561.
    PubMed         Abstract available

  11. HALIMI H, Hesami Z, Asri N, Khorsand B, et al
    Exploring the biliary microbiome in hepatopancreatobiliary disorders: a comprehensive systematic review of microbial signatures and diagnostic potential.
    BMC Gastroenterol. 2025 Dec 17. doi: 10.1186/s12876-025-04551.
    PubMed         Abstract available

  12. LI J, Yangjin B, Zhu C, Xu W, et al
    Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
    BMC Gastroenterol. 2025;25:860.
    PubMed         Abstract available


    Dig Dis Sci

  13. DODGE JL, Kim B
    Branched-Chain Amino Acid Supplementation in Patients with Cirrhosis: Boon, Bust, or Bull?
    Dig Dis Sci. 2025 Dec 16. doi: 10.1007/s10620-025-09614.
    PubMed        


    Endoscopy

  14. SHI T, Huang J, Cheng G, Hu D, et al
    A case of cirrhosis with gastric varices and hypersplenism treated by endoscopic ultrasound-guided devascularization and partial splenic embolization (with video).
    Endoscopy. 2025;57.
    PubMed        

  15. TORRES JJ, Hijioka S, Nagashio Y, Harai S, et al
    Endoscopic recanalization of a complete choledochojejunal anastomotic stricture using the "piercing technique" via an endoscopic ultrasound-guided hepaticogastrostomy approach.
    Endoscopy. 2025;57.
    PubMed        


    Eur J Pediatr

  16. NAJIMI Z, ElSaboni L, Mtegha M, Jayaprakash K, et al
    Analysis of tissue copper levels as a reliable diagnostic tool in paediatric liver disease.
    Eur J Pediatr. 2025;185:23.
    PubMed         Abstract available


    Eur Radiol

  17. HEO S, Kim HY, Kim S, Choi S, et al
    Performance of simulated abbreviated liver MRI combined with CT for liver metastasis screening in rectal cancer staging.
    Eur Radiol. 2026;36:666-675.
    PubMed         Abstract available

  18. SUTTER O, de Senneville BD, Lafitte L, Voyer D, et al
    Toward perioperative, numerically assisted irreversible electroporation for hepatocellular carcinoma: clinical outcomes informed by numerical simulations.
    Eur Radiol. 2025 Dec 19. doi: 10.1007/s00330-025-12223.
    PubMed         Abstract available


    Gastrointest Endosc

  19. MAGAHIS PT, Hissong E, Hanscom M, Carr-Locke DL, et al
    Outcomes of Endoscopic ultrasound-guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique.
    Gastrointest Endosc. 2026;103:98-108.
    PubMed         Abstract available


    Hepatology

  20. RUAN Q, Chen T, Kim M, Yang H, et al
    An alpha-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer.
    Hepatology. 2025 Dec 8. doi: 10.1097/HEP.0000000000001639.
    PubMed         Abstract available

  21. FORTUNY M, De Rosa A, Roca I, Ouchi D, et al
    Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria.
    Hepatology. 2025 Dec 15. doi: 10.1097/HEP.0000000000001630.
    PubMed         Abstract available

  22. LI L, Fang Y, Zhang J, Song M, et al
    Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophage.
    Hepatology. 2025 Dec 16. doi: 10.1097/HEP.0000000000001646.
    PubMed         Abstract available

  23. KHAN S
    PSC and HCC: Age and cirrhosis draw the line on risk.
    Hepatology. 2026;83:1.
    PubMed        

  24. WILECHANSKY RM
    Breaching the blood-brain barrier: Functional MRI changes in covert hepatic encephalopathy.
    Hepatology. 2026;83:4-5.
    PubMed        

  25. PREMKUMAR M, Kajal K
    Reply to 'Nuances in POCUS-guided hemodynamic assessment in cirrhosis'.
    Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001653.
    PubMed        

  26. KORATALA A, Argaiz ER
    Nuances in POCUS-guided hemodynamic assessment in cirrhosis.
    Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001648.
    PubMed        

  27. HARRISON SA, Dubourg J, Knott M, Colca J, et al
    Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:169-177.
    PubMed         Abstract available

  28. CARLINI LE, Fernandez AC, Mellinger JL
    Sex and gender in alcohol use disorder and alcohol-associated liver disease in the United States: A narrative review.
    Hepatology. 2026;83:178-194.
    PubMed         Abstract available

  29. KOH B, Xiao J, Ng CH, Law M, et al
    Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.
    Hepatology. 2026;83:117-126.
    PubMed         Abstract available

  30. PANAGIOTOPOULOS N, Wolfson T, Harris DT, Batakis D, et al
    Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:127-141.
    PubMed         Abstract available

  31. HAZARI Y, Habbouche L, Garcia Lopez VA, Urra H, et al
    Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the downregulation of the proteostasis factor P4HB/PDIA1.
    Hepatology. 2026;83:75-93.
    PubMed         Abstract available


    J Clin Oncol

  32. KAWAGUCHI Y, Kashiwabara K, Matsuyama Y, Kokudo N, et al
    Reply to: "Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study" and "Methodologic and Reporting Gaps in the SURF Trial".
    J Clin Oncol. 2025 Dec 19:JCO2502390. doi: 10.1200/JCO-25-02390.
    PubMed        

  33. VITALE A, Mansournia MA, Ponziani FR, Rovetta A, et al
    Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study.
    J Clin Oncol. 2025 Dec 19:JCO2501536. doi: 10.1200/JCO-25-01536.
    PubMed        


    J Hepatol

  34. LEVY C, Abouda GF, Bilir BM, Bonder A, et al
    Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
    J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available

  35. ARINO S, Ferrer-Lorente R, Serrano G, Zanatto L, et al
    Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease.
    J Hepatol. 2026;84:135-149.
    PubMed         Abstract available

  36. XU D, Zhang Z, Zhu Z, Wei W, et al
    Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels.
    J Hepatol. 2026;84:165-180.
    PubMed         Abstract available

  37. MATZ-SOJA M, Berg T, Kietzmann T
    Sex-related variations in liver homeostasis and disease: From zonation dynamics to clinical implications.
    J Hepatol. 2026;84:181-193.
    PubMed         Abstract available

  38. VILAR-GOMEZ E, Nephew L, Gawrieh S, Vuppalanchi R, et al
    Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States.
    J Hepatol. 2026;84:18-34.
    PubMed         Abstract available

  39. DU K, Umbaugh DS, Ren N, Diehl AM, et al
    Cellular senescence in liver diseases: From molecular drivers to therapeutic targeting.
    J Hepatol. 2026;84:194-212.
    PubMed         Abstract available

  40. HIRSCHFIELD GM, Kowdley KV, Trivedi PJ, Eksteen B, et al
    Phase II INTEGRIS-PSC trial of bexotegrast, an alphavbeta6/alphavbeta1 integrin inhibitor, in primary sclerosing cholangitis.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02498-5. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available


    N Engl J Med

  41. MEYA DB, Cresswell FV, Dai B, Engen N, et al
    Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
    N Engl J Med. 2025;393:2434-2446.
    PubMed         Abstract available


    PLoS One

  42. AYATI FIROOZABADI A, Elahi Vahed I, Lotfi P, Geshani A, et al
    The reciprocal relationship between non-alcoholic fatty liver disease and hypothyroidism: A systematic review and meta-analysis of about 39 million individuals.
    PLoS One. 2025;20:e0338413.
    PubMed         Abstract available

  43. BOONKAYA S, Pattarawongpaiboon C, Thaimai P, Ananchuensook P, et al
    Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study.
    PLoS One. 2025;20:e0337351.
    PubMed         Abstract available


    Radiology

  44. ZHU L, Jiang B, Fei X, Xu Y, et al
    Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy.
    Radiology. 2025;317:e251698.
    PubMed         Abstract available

  45. XIAO Z, Liu X
    Hepatocellular Carcinoma Presenting as Bile Duct Tumor Thrombus without Obvious Intrahepatic Mass.
    Radiology. 2025;317:e251418.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.